Aurobindo Pharma shares fall after USFDA warning letter
New Delhi: Shares of Aurobindo Pharma on Friday dipped over 3 per cent after the company said it has received a warning letter from the US health regulator for its Hyderabad-based Unit I, an API (Active Pharmaceutical Ingredient) manufacturing facility.
The stock tumbled 3.17 per cent to settle at Rs 695.15 on BSE. During the day, it tanked 4.65 per cent to Rs 684.50. On NSE, it dipped 3.12 per cent to close at Rs 695.15.In volume terms, 3.50 lakh shares were traded on BSE and over 58.79 lakh on NSE.
The action follows the recent inspection of the facility by the US Food and Drug Administration (USFDA) in August 2021, the drugmaker said in a regulatory filing on Friday.
"The company believes that this will not impact the existing business from this facility," it noted.
The drugmaker stated that it will be engaging with the regulator and is fully committed to resolving the issue at the earliest.
The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe, it noted.
A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations.
The letter identifies the violation, such as poor manufacturing practices, problems with claims for what a product can do, or incorrect directions for use.
The letter also makes clear that the company must correct the problem and provides directions and a timeframe of its plans for correction.
FDA then checks to ensure that the company's corrections are adequate.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.